Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | DGAT1 | O75907 | 16/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2311870 | 1.00 | KMT2A (0.53) | KMT2ADGAT1GAAMEN1ALDH1A1 | |
| SCHEMBL2312162 | 1.00 | KMT2A (0.53) | KMT2ADGAT1GAAMEN1ALDH1A1 | |
| SCHEMBL2309877 | 0.89 | DGAT1 (0.51) | KMT2ADGAT1GAAMEN1ALDH1A1 | |
| SCHEMBL2309730 | 0.89 | DGAT1 (0.51) | KMT2ADGAT1GAAMEN1ALDH1A1 | |
| SCHEMBL12430012 | 0.89 | DGAT1 (0.51) | KMT2ADGAT1GAAMEN1ALDH1A1 | |
| SCHEMBL2312694 | 0.89 | DGAT1 (0.51) | KMT2ADGAT1GAAMEN1ALDH1A1 | |
| SCHEMBL2306562 | 0.84 | SMN1; SMN2 (0.45) | KMT2ADGAT1GAAMEN1ALDH1A1 | |
| SCHEMBL2308736 | 0.84 | SMN1; SMN2 (0.45) | KMT2ADGAT1GAAMEN1ALDH1A1 | |
| SCHEMBL2306382 | 0.84 | DGAT1 (0.60) | KMT2ADGAT1MEN1ALDH1A1MAPT | |
| SCHEMBL2306376 | 0.84 | DGAT1 (0.60) | KMT2ADGAT1MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | claimed |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER | 2009-10-29 | — | — | US | claimed |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2009-08-06 | — | — | US | claimed |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | KMT2A 627/4885DGAT1 34/4885GAA 307/4885 |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | KMT2A 627/4885DGAT1 34/4885GAA 307/4885 |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, LIPC | KMT2A 627/4885DGAT1 34/4885GAA 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.